Efficacia e sicurezza del teplizumab nei partecipanti giapponesi con diabete di tipo 1 di tipo 1 (KIBOU-T1D)
Efficacia e sicurezza di teplizumab nel trattamento di partecipanti giapponesi pediatrici e adulti di età compresa tra 8 e 34 anni con diabete di tipo 1 in stadio 2: uno studio multicentrico, randomizzato, in aperto e controllato.
This is a parallel, Phase 2, two-arm study to assess the efficacy and safety of 14-days intravenous (IV) infusion of teplizumab treatment.
Teplizumab has been approved by FDA to delay the onset of Stage 3 Type 1 Diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D. The dose regimen of teplizumab in this study is consistent with the regimen approved by US FDA.
Given prior clinical studies conducted in Western countries, this design is appropriate to assess the efficacy, safety and tolerability, pharmacokinetic, pharmacodynamic, and immunogenicity of a 14-day IV infusion regimen of teplizumab in Japanese Stage 2 T1D participants aged 1 to 34 years.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Total study duration is approximately 756 days.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
Fukuoka, Giappone, 812-0025
- Investigational Site Number : 3920017
-
Kyoto, Giappone, 606-8507
- Investigational Site Number : 3920016
-
Nagasaki, Giappone, 852-8501
- Investigational Site Number : 3920014
-
Osaka, Giappone, 545-8586
- Investigational Site Number : 3920004
-
Tokyo, Giappone, 101-8309
- Investigational Site Number : 3920020
-
Tokyo, Giappone, 162-8666
- Investigational Site Number : 3920003
-
-
Chiba
-
Ichikawa, Chiba, Giappone, 272-0827
- Investigational Site Number : 3920015
-
-
Gunma
-
Maebashi, Gunma, Giappone, 371-8511
- Investigational Site Number : 3920011
-
-
Hokkaido
-
Sapporo, Hokkaido, Giappone, 060-8543
- Investigational Site Number : 3920006
-
-
Hyōgo
-
Kobe, Hyōgo, Giappone, 650-0017
- Investigational Site Number : 3920018
-
-
Ishikawa-ken
-
Kanazawa, Ishikawa-ken, Giappone, 920-8641
- Investigational Site Number : 3920009
-
-
Iwate
-
Yahaba, Iwate, Giappone, 028-3695
- Investigational Site Number : 3920007
-
-
Kanagawa
-
Yokohama, Kanagawa, Giappone, 222-0036
- Investigational Site Number : 3920019
-
-
Saitama
-
Iruma, Saitama, Giappone, 350-0495
- Investigational Site Number : 3920001
-
-
Yamanashi
-
Chūō, Yamanashi, Giappone, 409-3898
- Investigational Site Number : 3920010
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Male or female Japanese participant, 1 (inclusive) to 34 years (inclusive) of age, at the time of signing the informed consent. Japanese: born in Japan or ethnic Japanese born outside of Japan, and a descendent of 4 ethnic Japanese grandparents who were all born in Japan.
- Confirmed diagnosis of Stage 2 T1D based on following criteria:
- Participant is positive for 2 or more T1D related auto-antibodies (confirmed by written medical history and/or obtained at study screening). The autoantibodies that are to be confirmed are anti-GAD (glutamic acid decarboxylase), anti-IA2 (insulinoma-associated antigen 2), anti-insulin, anti-ZnT8 (zinc transporter 8), and/or ICA (islet cell antibody).
- Oral glucose tolerance test (OGTT) or blood HbA1c confirms the participant has dysglycemia without overt hyperglycemia.
- Participant must be in good health (except for being Stage 2 T1D) as determined by medical e)valuation including medical history, physical examination, laboratory tests, and electrocardiogram (ECG) XE " ECG " \f Abbreviation \t "electrocardiogram" .
- Participant is up to date with routine age-appropriate immunizations according to current local specific guideline prior to randomization.
- Female participants should use contraceptives consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- A female participant is considered fertile (woman of childbearing potential - WOCBP) from the time of menarche until becoming postmenopausal unless permanently sterile. Female participants are eligible to participate if one of the following conditions applies:
- Is a woman of nonchildbearing potential (WONCBP) OR
- Is a WOCBP and agrees to keep abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent, or use other highly effective contraceptive method, from signing of the informed consent to at least 3 months and 2 weeks after randomization and agrees not to donate or cryopreserve eggs (ova, oocytes) for the purpose of reproduction during this period.
A WOCBP must have at least a negative highly sensitive pregnancy test within 48 hours before the administration of study intervention.
If a urine test cannot be confirmed as negative (eg, an ambiguous result), a blood pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
Participants are excluded from the study if any of the following criteria apply:
- Any presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, dermatologic, hepatic, renal, metabolic (except Stage 2 T1D), hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness.
- Participant has clinical signs and symptoms consistent with COVID19, eg, fever, dry cough, dyspnea, loss of taste and smell, sore throat, fatigue or confirmed infection by appropriate laboratory test within the last 4 weeks prior to Screening. Participant who had severe course of COVID-19 (ie, hospitalization, extracorporeal membrane oxygenation, mechanically ventilated).
- For participant ≥18 years, blood donation of 400 mL within 12 weeks (male) or 16 weeks (female), 200 mL within 4 weeks or apheresis donation within 2 weeks before randomization; for participant <18 years, blood donation of any volume within 16 weeks before randomization; for any participant, blood transfusion (any volume) within 2 months before randomization.
- Presence or history of drug hypersensitivity to any biologic medication, or clinically significant allergic disease as diagnosed and treated by a physician. Participants with known hypersensitivity to teplizumab or components of the teplizumab injection (including sodium phosphate, sodium chloride, polysorbate 80).
- Participants with a history of active or latent or inactive tuberculosis (TB), including chest X-ray consistent with TB, regardless of treatment, or have a positive QuantiFERON-TB Gold test or T-SPOT TB test at screening.
- At screening, participant has laboratory or clinical evidence of acute or clinically active infection with Epstein Barr virus (EBV), or history of infectious mononucleosis within 3 months before enrollment.
- At screening, participant has laboratory or clinical evidence of acute or clinically active infection with cytomegalovirus (CMV).
- Participants with a history of invasive opportunistic infections, such as histoplasmosis, listeriosis, coccidioidomycosis, candidiasis, pneumocystis jirovecii, aspergillosis, irrespective of resolution.
- Participants have other autoimmune diseases, except clinically stable autoimmune thyroid disease, or celiac disease.
- Participants with a history of malignancy occurring within 5 years before randomization (except successfully treated carcinoma in situ of the cervix, or adequately treated nonmetastatic squamous cell or basal cell carcinoma of the skin).
- Participants with fever (temperature ≥38.0°C) within 48 hours before randomization; or with chronic persistent or recurring infection(s) requiring active treatment with antibiotics, antiviral or antifungals within 4 weeks before randomization; or with other frequent recurrent infections deemed unacceptable as per Investigator's judgement.
- If female, pregnancy (defined as positive blood or urine pregnancy test) or breast-feeding.
- Participant has recent or planned vaccinations as follows:
- Live vaccines: within 8 weeks before randomization, and/or within 54 weeks after randomization.
- Non-live vaccines: any initial non-live vaccination within 2 weeks before randomization, and/or within 8 weeks after randomization.
- Participant has a current or prior (within 30 days before randomization) treatment that is known to cause a significant, ongoing change in the course of T1D or immunologic status, including high dose, inhaled, extensive topical, or systemic glucocorticoids.
- Participant has a current or prior (within 30 days before randomization) treatment that is known to significantly influence glucose tolerance (anti-hyperglycemic agents, atypical antipsychotics, diphenylhydantoin, niacin etc.).
- Participant has received any anti-CD3 (cluster of differentiation 3) antibody treatment (including teplizumab) before randomization.
- Participant who has received any biologic therapy within five half-lives of the therapy or within 6 months before randomization whichever is longer, or plan to receive any biologic therapy within 6 weeks after randomization.
- Any participant enrolled or having participated, in this or any other clinical study involving an investigational medicinal product (IMP) or in any other type of medical research and is still in the exclusion period according to applicable regulations (eg, having received an IMP of new active pharmaceutical ingredient (API) within 4 months or that of an approved API within 3 months before the administration of this study's IMP).
- Participant has any of the following hematologic parameters before randomization:
- Lymphocyte count <1.0 ×109/L.
- Neutrophil count <1.5 ×109/L.
- Platelet count <150 ×109/L.
- Hemoglobin <100 g/L.
- Participant has any of the following liver function test abnormalities before randomization:
- AST >2 × ULN (upper limit normal).
- ALT >2 × ULN.
- Total bilirubin >1.5 × ULN with the exception of participants with the diagnosis of Gilbert's syndrome who may be eligible provided they have no other causes leading to hyperbilirubinemia.
- Positive result on any of the following tests:
- Hepatitis B surface antigen or hepatitis B core antibody confirmed by positive HBV-DNA (hepatitis B virus DNA).
- Anti-hepatitis C virus antibody confirmed by positive HCV-RNA (hepatitis C virus RNA).
- Human immunodeficiency virus antigen/ antibodies.
- Positive SARS-CoV-2 test.
- Participant who has contraindications or known allergy to both nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen, or anti-histamines and in the opinion of the Investigator, cannot participate in the study.
- Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Teplizumab
Participants will receive Teplizumab via IV infusion |
Pharmaceutical form:Solution for injection-Route of administration:Intravenous infusion
Altri nomi:
|
|
Nessun intervento: Control
Participants will receive no treatment in the control group |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Numero di partecipanti con diabete di tipo 1 allo stadio 3 basato sui criteri dell'American Diabetes Association
Lasso di tempo: Dalla linea di base fino alla settimana 104
|
Dalla linea di base fino alla settimana 104
|
|
|
Cambia dal basale nell'area sotto la curva (AUC) di c-peptide
Lasso di tempo: Dalla linea di base fino alla settimana 104
|
Dalla linea di base fino alla settimana 104
|
|
|
Change from baseline in AUC of endogenous insulin
Lasso di tempo: From baseline up to Week 104
|
From baseline up to Week 104
|
|
|
Number of participants with TEAEs, SAEs, AEs leading to permanent study intervention- or study discontinuation; AEs of special interest; number of participants with clinically significant changes in vital signs, ECG, and/or safety laboratory test
Lasso di tempo: Throughout the study, approximately 756 days
|
TEAE: treatment-emerged adverse event; SAE: serious adverse event; AE: adverse event |
Throughout the study, approximately 756 days
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Modifica dal basale nel glucosio plasmatico a digiuno (FPG) da un test di tolleranza al glucosio orale
Lasso di tempo: Dal basale fino alla settimana 104
|
Dal basale fino alla settimana 104
|
|
Variazione rispetto al basale della glicemia a 2 ore da un test di tolleranza al glucosio orale
Lasso di tempo: Dalla linea di base fino alla settimana 104
|
Dalla linea di base fino alla settimana 104
|
|
Variazione rispetto al basale dell'emoglobina A1c (HbA1c)
Lasso di tempo: Dalla linea di base fino alla settimana 104
|
Dalla linea di base fino alla settimana 104
|
|
Concentrazione sierica di teplizumab
Lasso di tempo: Dal giorno 1 al giorno 28
|
Dal giorno 1 al giorno 28
|
|
Numero di partecipanti con anticorpi anti-farmaco
Lasso di tempo: Dalla linea di base fino alla settimana 104
|
Dalla linea di base fino alla settimana 104
|
|
Numero di partecipanti con anticorpi neutralizzanti
Lasso di tempo: Dal basale fino alla settimana 104
|
Dal basale fino alla settimana 104
|
Collaboratori e investigatori
Sponsor
Sponsor
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- ACT18487
- U1111-1308-1324 (Identificatore di registro: ICTRP)
- jRCT2031240637 (Identificatore di registro: JRCT)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .